AMY-101 (acetate)

AMY-101 (acetate)

• UNSPSC Description: AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].
• Target Antigen: Complement System; SARS-CoV
• Type: Peptides
• Related Pathways: Anti-infection;Immunology/Inflammation
• Applications: COVID-19-anti-virus
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/amy-101-acetate.html
• Purity: 99.93
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)
• Smiles: CC(O)=O.CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@H]([C@@H](C)CC)NC([C@H](N)CC4=CC=C(C=C4)O)=O)=O)C(N(C)[C@H](C(N)=O)[C@@H](C)CC)=O)=O)CCCNC(N)=N)=O)CC5=CN=CN5)=O)C)=O)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1
• Molecular Weight: 1849.16
• References & Citations: [1]Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215.|[2]Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450.|[3]1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Sci Total Environ. 2024 Mar 13:171681.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
• Clinical Information: Phase 2